vs
Side-by-side financial comparison of Aquestive Therapeutics, Inc. (AQST) and TRANSACT TECHNOLOGIES INC (TACT). Click either name above to swap in a different company.
Aquestive Therapeutics, Inc. is the larger business by last-quarter revenue ($13.0M vs $11.5M, roughly 1.1× TRANSACT TECHNOLOGIES INC). On growth, TRANSACT TECHNOLOGIES INC posted the faster year-over-year revenue change (11.9% vs 9.7%). TRANSACT TECHNOLOGIES INC produced more free cash flow last quarter ($589.0K vs $-8.6M). Over the past eight quarters, Aquestive Therapeutics, Inc.'s revenue compounded faster (3.9% CAGR vs 3.5%).
Aquestive Therapeutics is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for central nervous system disorders. It leverages proprietary drug delivery technologies to create accessible, patient-friendly therapeutic options, serving healthcare providers and patients across North America and European markets, with core offerings addressing unmet needs in neurology and psychiatry.
Roper Technologies, Inc. is a holding company that owns companies in the technology sector.
AQST vs TACT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.0M | $11.5M |
| Net Profit | $-31.9M | — |
| Gross Margin | 55.2% | 47.6% |
| Operating Margin | -221.6% | -10.1% |
| Net Margin | -244.8% | — |
| Revenue YoY | 9.7% | 11.9% |
| Net Profit YoY | -86.8% | — |
| EPS (diluted) | $-0.26 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.0M | $11.5M | ||
| Q3 25 | $12.8M | $13.2M | ||
| Q2 25 | $10.0M | $13.8M | ||
| Q1 25 | $8.7M | $13.1M | ||
| Q4 24 | $11.9M | $10.2M | ||
| Q3 24 | $13.5M | $10.9M | ||
| Q2 24 | $20.1M | $11.6M | ||
| Q1 24 | $12.1M | $10.7M |
| Q4 25 | $-31.9M | — | ||
| Q3 25 | $-15.4M | $15.0K | ||
| Q2 25 | $-13.5M | $-143.0K | ||
| Q1 25 | $-22.9M | $19.0K | ||
| Q4 24 | $-17.1M | — | ||
| Q3 24 | $-11.5M | $-551.0K | ||
| Q2 24 | $-2.7M | $-319.0K | ||
| Q1 24 | $-12.8M | $-1.0M |
| Q4 25 | 55.2% | 47.6% | ||
| Q3 25 | 64.8% | 49.8% | ||
| Q2 25 | 54.4% | 48.2% | ||
| Q1 25 | 58.1% | 48.7% | ||
| Q4 24 | 61.9% | 44.2% | ||
| Q3 24 | 67.2% | 48.1% | ||
| Q2 24 | 77.5% | 52.7% | ||
| Q1 24 | 63.6% | 52.6% |
| Q4 25 | -221.6% | -10.1% | ||
| Q3 25 | -89.6% | 0.1% | ||
| Q2 25 | -113.6% | -1.9% | ||
| Q1 25 | -222.1% | -0.1% | ||
| Q4 24 | -114.4% | -10.3% | ||
| Q3 24 | -61.2% | -7.7% | ||
| Q2 24 | 0.3% | -3.8% | ||
| Q1 24 | -74.3% | -12.2% |
| Q4 25 | -244.8% | — | ||
| Q3 25 | -120.6% | 0.1% | ||
| Q2 25 | -135.4% | -1.0% | ||
| Q1 25 | -263.0% | 0.1% | ||
| Q4 24 | -143.7% | — | ||
| Q3 24 | -85.0% | -5.1% | ||
| Q2 24 | -13.7% | -2.8% | ||
| Q1 24 | -106.4% | -9.7% |
| Q4 25 | $-0.26 | $-0.11 | ||
| Q3 25 | $-0.14 | $0.00 | ||
| Q2 25 | $-0.14 | $-0.01 | ||
| Q1 25 | $-0.24 | $0.00 | ||
| Q4 24 | $-0.18 | $-0.80 | ||
| Q3 24 | $-0.13 | $-0.06 | ||
| Q2 24 | $-0.03 | $-0.03 | ||
| Q1 24 | $-0.17 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $20.4M |
| Total DebtLower is stronger | $27.5M | — |
| Stockholders' EquityBook value | $-33.7M | $31.1M |
| Total Assets | $160.4M | $44.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $20.4M | ||
| Q3 25 | $129.1M | $20.0M | ||
| Q2 25 | $60.5M | $17.7M | ||
| Q1 25 | $68.7M | $14.2M | ||
| Q4 24 | $71.5M | $14.4M | ||
| Q3 24 | $77.9M | $11.3M | ||
| Q2 24 | $89.9M | $11.1M | ||
| Q1 24 | $95.2M | $10.6M |
| Q4 25 | $27.5M | — | ||
| Q3 25 | $45.0M | — | ||
| Q2 25 | $45.0M | — | ||
| Q1 25 | $45.0M | — | ||
| Q4 24 | $32.5M | — | ||
| Q3 24 | $45.0M | — | ||
| Q2 24 | $45.0M | — | ||
| Q1 24 | $45.0M | — |
| Q4 25 | $-33.7M | $31.1M | ||
| Q3 25 | $-4.1M | $31.8M | ||
| Q2 25 | $-72.6M | $31.3M | ||
| Q1 25 | $-60.9M | $30.9M | ||
| Q4 24 | $-60.2M | $30.6M | ||
| Q3 24 | $-45.4M | $38.4M | ||
| Q2 24 | $-35.5M | $38.5M | ||
| Q1 24 | $-36.3M | $38.6M |
| Q4 25 | $160.4M | $44.8M | ||
| Q3 25 | $163.6M | $45.0M | ||
| Q2 25 | $93.7M | $44.5M | ||
| Q1 25 | $102.2M | $44.2M | ||
| Q4 24 | $101.4M | $44.0M | ||
| Q3 24 | $110.0M | $50.5M | ||
| Q2 24 | $117.6M | $50.4M | ||
| Q1 24 | $129.5M | $51.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-8.5M | $609.0K |
| Free Cash FlowOCF − Capex | $-8.6M | $589.0K |
| FCF MarginFCF / Revenue | -65.7% | 5.1% |
| Capex IntensityCapex / Revenue | 0.7% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-53.0M | $7.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-8.5M | $609.0K | ||
| Q3 25 | $-12.6M | $3.6M | ||
| Q2 25 | $-7.9M | $3.6M | ||
| Q1 25 | $-23.4M | $-161.0K | ||
| Q4 24 | $-6.5M | $2.4M | ||
| Q3 24 | $-11.9M | $327.0K | ||
| Q2 24 | $-7.0M | $636.0K | ||
| Q1 24 | $-10.4M | $-1.5M |
| Q4 25 | $-8.6M | $589.0K | ||
| Q3 25 | $-12.9M | $3.6M | ||
| Q2 25 | $-8.0M | $3.6M | ||
| Q1 25 | $-23.5M | $-171.0K | ||
| Q4 24 | $-6.5M | $2.4M | ||
| Q3 24 | $-12.0M | $259.0K | ||
| Q2 24 | $-7.0M | $499.0K | ||
| Q1 24 | $-10.4M | $-1.6M |
| Q4 25 | -65.7% | 5.1% | ||
| Q3 25 | -100.6% | 27.1% | ||
| Q2 25 | -80.2% | 25.9% | ||
| Q1 25 | -269.9% | -1.3% | ||
| Q4 24 | -54.8% | 23.2% | ||
| Q3 24 | -88.3% | 2.4% | ||
| Q2 24 | -35.0% | 4.3% | ||
| Q1 24 | -86.4% | -14.9% |
| Q4 25 | 0.7% | 0.2% | ||
| Q3 25 | 1.8% | 0.5% | ||
| Q2 25 | 1.1% | 0.1% | ||
| Q1 25 | 1.5% | 0.1% | ||
| Q4 24 | 0.1% | 0.1% | ||
| Q3 24 | 0.6% | 0.6% | ||
| Q2 24 | 0.2% | 1.2% | ||
| Q1 24 | 0.2% | 1.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 242.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -8.47× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
